Global Pulmonary Arterial Hypertension (PAH) Market August 2016 | Page 2

Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Opportunities and Forecasts (2016-2021) (By Drug Class -Endothelin Receptor Antagonists, Prostacyclin & Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa) Global Pulmonary Arterial Hypertension Market: Trends, Opportunities and Forecasts (2016-2021), Global Pulmonary Arterial Hypertension market is projected to exhibit a CAGR of over ~4.95% during 2016 - 2021. On the basis of market segment, Global Pulmonary Arterial Hypertension Market has been segmented By Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa) The report suggests that rising development of pipeline drugs in PAH combined with the growing awareness of the disease majorly in developed countries has resulted in t he growth of PAH market. Access Complete Report at http://www.reportsnreports.com/reports/657034-global-pulmonaryarterial-hypertension-pah-market-by-drug-class-by-region-by-country-opportunities-and-forecasts2016-2021-by-drug-class-endothelin-receptor-antagonists-prostacyclin-prostacyclin-analogsphosphodiesterase-v-inhibitors-others-by-region-north-america-europe-apac-latin-america-meaby-country-usa-canada-uk-germany-japan-brazil-south-africa-.html. Order this report by calling [phone] or Send an email to [email protected] with your contact details and questions if any. © ReportsnReports.com / Contact [email protected] 2